

Theodoros Foukakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1894020/publications.pdf>

Version: 2024-02-01

99
papers

5,123
citations

159358

30
h-index

98622

67
g-index

102
all docs

102
docs citations

102
times ranked

8088
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	13.9	1,542
2	Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. <i>Cell</i> , 2018, 173, 879-893.e13.	13.5	777
3	An HIF-1 α /VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. <i>Cancer Cell</i> , 2017, 32, 669-683.e5.	7.7	352
4	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
5	Involvement of the PAX8/Peroxisome Proliferator-Activated Receptor β Rearrangement in Follicular Thyroid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4440-4445.	1.8	204
6	External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. <i>JAMA Oncology</i> , 2020, 6, 1581.	3.4	148
7	Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. <i>Nature Communications</i> , 2017, 8, 228.	5.8	105
8	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
9	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	3.8	79
10	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. <i>Clinical Cancer Research</i> , 2019, 25, 5717-5726.	3.2	71
11	Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR β fusion oncogene. <i>Oncogene</i> , 2005, 24, 1467-1476.	2.6	68
12	Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 553-560.	1.1	68
13	First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. <i>Radiotherapy and Oncology</i> , 2015, 114, 322-327.	0.3	61
14	Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. <i>Oncotarget</i> , 2016, 7, 74966-74978.	0.8	61
15	STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. <i>Cancers</i> , 2019, 11, 1479.	1.7	55
16	Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2008, 15, 801-815.	1.6	53
17	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 628.	1.7	51
18	Proteomic profiling of follicular and papillary thyroid tumors. <i>European Journal of Endocrinology</i> , 2012, 166, 657-667.	1.9	48

#	ARTICLE	IF	CITATIONS
19	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. <i>Breast Cancer Research</i> , 2019, 21, 34.	2.2	48
20	Advances in the treatment of patients with gastric adenocarcinoma. <i>Acta Oncol</i> 2007, 46, 277-285.	0.8	47
21	Molecular Markers for Discrimination of Benign and Malignant Follicular Thyroid Tumors. <i>Tumor Biology</i> , 2006, 27, 211-220.	0.8	46
22	A PCR-based expression signature of malignancy in follicular thyroid tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 381-391.	1.6	46
23	Molecular Cytogenetic Profiles of Novel and Established Human Anaplastic Thyroid Carcinoma Models. <i>Thyroid</i> , 2007, 17, 289-301.	2.4	43
24	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 7512-7520.	3.2	43
25	The Ras Effector NRE1A Is Suppressed in Follicular Thyroid Carcinomas with a PAX8-PPAR γ Fusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1143-1149.	1.8	42
26	Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial. <i>Oncologist</i> , 2020, 25, 23-32.	1.9	41
27	Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102257.	3.4	40
28	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488.	2.9	37
29	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 958-967.	0.4	34
30	Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca ²⁺ -Binding Protein S100A6 in Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2010, 20, 1067-1076.	2.4	32
31	Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 407-414.	1.1	30
32	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1360.	3.4	30
33	Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study. <i>Npj Breast Cancer</i> , 2020, 6, 36.	2.3	29
34	Anaplastic carcinoma of the thyroid gland: Treatment and outcome over 13 years at one institution. <i>Journal of Surgical Oncology</i> , 2012, 106, 981-986.	0.8	28
35	Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. <i>Annals of Oncology</i> , 2019, 30, 1044-1050.	0.6	28
36	The Ras effectors NRE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. <i>Endocrine-Related Cancer</i> , 2007, 14, 125-134.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. <i>Molecular Oncology</i> , 2016, 10, 517-525.	2.1	21
38	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1466017.	2.1	18
39	Programmed deathâ€ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21â€gene and 70â€gene signatures in estrogen receptorâ€positive disease. <i>Molecular Oncology</i> , 2020, 14, 951-963.	2.1	18
40	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7225-7231.	3.2	17
41	Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?. <i>Journal of Clinical Oncology</i> , 2019, 37, 501-501.	0.8	17
42	A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. <i>Acta OncolÃ³gica</i> , 2015, 54, 527-534.	0.8	15
43	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1573-1579.	0.8	15
44	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 91-101.	2.0	15
45	Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. <i>Annals of Oncology</i> , 2019, 30, 109-114.	0.6	15
46	Efficacy and safety of tailored and doseâ€dense adjuvant chemotherapy and trastuzumab for resected HER2â€positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	2.0	14
47	Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. <i>Clinical Nutrition</i> , 2021, 40, 3370-3378.	2.3	14
48	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1384-1391.	2.1	13
49	Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9635-E9644.	3.3	12
50	PD-1 protein and gene expression as prognostic factors in early breast cancer. <i>ESMO Open</i> , 2020, 5, e001032.	2.0	12
51	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. <i>Acta OncolÃ³gica</i> , 2020, 59, 1382-1387.	0.8	11
52	Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. <i>BMC Cancer</i> , 2013, 13, 473.	1.1	10
53	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta OncolÃ³gica</i> , 2020, 59, 75-81.	0.8	10
54	Chemotherapy use near the end-of-life in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 645-651.	1.1	10

#	ARTICLE	IF	CITATIONS
55	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2417-2426.	3.2	8
56	Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. <i>Acta Oncologica</i> , 2017, 56, 1143-1151.	0.8	8
57	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2615.	1.7	7
58	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. <i>International Journal of Oncology</i> , 2005, 26, 141.	1.4	6
59	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 87-96.	1.1	6
60	Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4655.	1.7	6
61	Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 319-326.	1.1	5
62	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 349-355.	1.1	5
63	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
64	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. <i>Cancers</i> , 2022, 14, 1999.	1.7	5
65	Validation of a novel procedure for quantification of the formation of phosphoramidate mustard by individuals treated with cyclophosphamide. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 549-558.	1.1	4
66	Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 703-712.	1.1	3
67	Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer. <i>Molecular Oncology</i> , 2022, 16, 2413-2431.	2.1	3
68	Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 553-553.	0.8	3
69	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021, 7, 144.	2.3	3
70	Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, e12620-e12620.	0.8	3
71	Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?. <i>Annals of Oncology</i> , 2018, 29, 2278-2280.	0.6	2
72	Ribociclib in premenopausal women with advanced breast cancer. <i>Lancet Oncology</i> , The, 2018, 19, 850-852.	5.1	2

#	ARTICLE	IF	CITATIONS
73	Axillary evaluation in ductal cancer <i>in situ</i> of the breast: challenging the diagnostic accuracy of clinical practice guidelines. <i>British Journal of Surgery</i> , 2021, 108, 1120-1125.	0.1	2
74	A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10083-10083.	0.8	2
75	Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 583-583.	0.8	2
76	Prognostic role of Ki67 determined on metastatic tissue of patients with advanced breast cancer. <i>Breast</i> , 2011, 20, S28-S29.	0.9	1
77	RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1280-1281.	3.0	1
78	Expert Discussion: HER2-Positive Breast Cancer. <i>Breast Care</i> , 2021, 16, 422-428.	0.8	1
79	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 538-538.	0.8	1
80	Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
81	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. <i>International Journal of Oncology</i> , 2005, 26, 141-9.	1.4	1
82	Reply to A.Y. Lin. <i>Journal of Clinical Oncology</i> , 2017, 35, 121-122.	0.8	0
83	Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. <i>Npj Breast Cancer</i> , 2021, 7, 21.	2.3	0
84	Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11510-e11510.	0.8	0
85	Sequential metastatic biopsies and functional imaging in breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22120-e22120.	0.8	0
86	Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22090-e22090.	0.8	0
87	Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1044-1044.	0.8	0
88	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004â€“1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12036-e12036.	0.8	0
89	Regulation of PD-L1 in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23088-e23088.	0.8	0
90	Abstract 418: Adaptive resistance to chemotherapy in triple-negative breast cancer revealed by single cell DNA and RNA sequencing. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
91	Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.. Journal of Clinical Oncology, 2019, 37, e14284-e14284.	0.8	0
92	Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast cancer.. Journal of Clinical Oncology, 2019, 37, 550-550.	0.8	0
93	One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.. Journal of Clinical Oncology, 2020, 38, 590-590.	0.8	0
94	PD-1 protein and gene expression in early breast cancer: Prognostic implications.. Journal of Clinical Oncology, 2020, 38, 545-545.	0.8	0
95	Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. Cancer Research, 2022, 82, P4-12-01-P4-12-01.	0.4	0
96	Abstract P1-02-03: Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer. Cancer Research, 2022, 82, P1-02-03-P1-02-03.	0.4	0
97	Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study. Breast Cancer Research and Treatment, 2022, , 1.	1.1	0
98	Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.. Journal of Clinical Oncology, 2022, 40, 593-593.	0.8	0
99	Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.. Journal of Clinical Oncology, 2022, 40, e12598-e12598.	0.8	0